1. Home
  2. TDUP vs FDMT Comparison

TDUP vs FDMT Comparison

Compare TDUP & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ThredUp Inc.

TDUP

ThredUp Inc.

N/A

Current Price

$3.10

Market Cap

745.9M

ML Signal

N/A

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

N/A

Current Price

$12.06

Market Cap

695.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TDUP
FDMT
Founded
2009
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.9M
695.3M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
TDUP
FDMT
Price
$3.10
$12.06
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$8.17
$31.71
AVG Volume (30 Days)
3.0M
590.6K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
75.36
18.79
EPS
N/A
N/A
Revenue
$310,813,000.00
$85,209,000.00
Revenue This Year
$15.75
N/A
Revenue Next Year
$10.65
$70.28
P/E Ratio
N/A
N/A
Revenue Growth
19.53
230194.60
52 Week Low
$3.03
$5.97
52 Week High
$12.28
$14.00

Technical Indicators

Market Signals
Indicator
TDUP
FDMT
Relative Strength Index (RSI) 23.43 61.51
Support Level $3.08 $9.63
Resistance Level $5.13 $11.89
Average True Range (ATR) 0.30 0.61
MACD -0.29 0.19
Stochastic Oscillator 3.05 93.42

Price Performance

Historical Comparison
TDUP
FDMT

About TDUP ThredUp Inc.

ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Share on Social Networks: